Research
Differential expression of apoptotic genes PDIA3 and MAP3K5 distinguishes between low- and high-risk prostate cancer
-
* Corresponding author: Holger Sültmann h.sueltmann@dkfz.de
1 German Cancer Research Center, Division of Molecular Genome Analysis, Im Neuenheimer Feld 580, D-69120 Heidelberg, Germany
2 Abbott GmbH & Co. KG, Max-Planck Ring 2, Wiesbaden, Germany
3 University Clinics for Urology, Innsbruck Medical University, Anichstraße 35, A-6020 Innsbruck, Austria
4 Institute for Pathology, Innsbruck Medical University, Müllerstraße 40, A-6020 Innsbruck, Austria
5 Applied Biosystems, Grundstrasse 10, CH-6343 Rotkreuz, Switzerland
Molecular Cancer 2009, 8:130 doi:10.1186/1476-4598-8-130
Published: 27 December 2009Abstract
Background
Despite recent progress in the identification of genetic and molecular alterations in prostate cancer, markers associated with tumor progression are scarce. Therefore precise diagnosis of patients and prognosis of the disease remain difficult. This study investigated novel molecular markers discriminating between low and highly aggressive types of prostate cancer.
Results
Using 52 microdissected cell populations of low- and high-risk prostate tumors, we identified via global cDNA microarrays analysis almost 1200 genes being differentially expressed among these groups. These genes were analyzed by statistical, pathway and gene enrichment methods. Twenty selected candidate genes were verified by quantitative real time PCR and immunohistochemistry. In concordance with the mRNA levels, two genes MAP3K5 and PDIA3 exposed differential protein expression. Functional characterization of PDIA3 revealed a pro-apoptotic role of this gene in PC3 prostate cancer cells.
Conclusions
Our analyses provide deeper insights into the molecular changes occurring during prostate cancer progression. The genes MAP3K5 and PDIA3 are associated with malignant stages of prostate cancer and therefore provide novel potential biomarkers.